Search

Your search keyword '"Handley, Amanda"' showing total 36 results
Start Over Author "Handley, Amanda"
36 results on '"Handley, Amanda"'

1. Wastewater monitoring can anchor global disease surveillance systems

Author

Ahmed, Warish, Amman, Fabian, Aruna, Olusola, Badilla-Aguilar, Andrei, Bar-Or, Itay, Bergthaler, Andreas, Bines, Julie E, Bivins, Aaron W, Boehm, Alexandria B, Brault, Jean-Martin, Burnet, Jean-Baptiste, Chapman, Joanne R, Chaudhuri, Angela, de Roda Husman, Ana Maria, Delatolla, Robert, Dennehy, John J, Diamond, Megan Beth, Donato, Celeste, Duizer, Erwin, Egwuenu, Abiodun, Erster, Oran, Fatta-Kassinos, Despo, Gaggero, Aldo, Gilpin, Deirdre F, Gilpin, Brent J, Graber, Tyson E, Green, Christopher A, Handley, Amanda, Hewitt, Joanne, Holm, Rochelle H, Insam, Heribert, Johnson, Marc C, Johnson, Rabia, Jones, Davey L, Julian, Timothy R, Jyothi, Asha, Keshaviah, Aparna, Kohn, Tamar, Kuhn, Katrin G, La Rosa, Giuseppina, Lesenfants, Marie, Manuel, Douglas G, D'Aoust, Patrick M, Markt, Rudolf, McGrath, John W, Medema, Gertjan, Moe, Christine L, Murni, Indah Kartika, Naser, Humood, Naughton, Colleen C, Ogorzaly, Leslie, Oktaria, Vicka, Ort, Christoph, Karaolia, Popi, Patel, Ekta H, Paterson, Steve, Rahman, Mahbubur, Rivera-Navarro, Pablo, Robinson, Alex, Santa-Maria, Monica C, Scarpino, Samuel V, Schmitt, Heike, Smith, Theodore, Stadler, Lauren B, Stassijns, Jorgen, Stenico, Alberta, Street, Renee A, Suffredini, Elisabetta, Susswein, Zachary, Trujillo, Monica, Wade, Matthew J, Wolfe, Marlene K, Yakubu, Habib, Zanoli Sato, Maria Ines, and Diamond, Megan B

Published
2023
Full Text
View/download PDF

2. Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study

Author

Witte, Desiree, Handley, Amanda, Jere, Khuzwayo C, Bogandovic-Sakran, Nada, Mpakiza, Ashley, Turner, Ann, Pavlic, Daniel, Boniface, Karen, Mandolo, Jonathan, Ong, Darren Suryawijaya, Bonnici, Rhian, Justice, Frances, Bar-Zeev, Naor, Iturriza-Gomara, Miren, Ackland, Jim, Donato, Celeste M, Cowley, Daniel, Barnes, Graeme, Cunliffe, Nigel A, and Bines, Julie E

Published
2022
Full Text
View/download PDF

3. Rotavirus-Specific Maternal Serum Antibodies and Vaccine Responses to RV3-BB Rotavirus Vaccine Administered in a Neonatal or Infant Schedule in Malawi.

Author

Morgan, Benjamin, Lyons, Eleanor A., Handley, Amanda, Bogdanovic-Sakran, Nada, Pavlic, Daniel, Witte, Desiree, Mandolo, Jonathan, Turner, Ann, Jere, Khuzwayo C., Justice, Frances, Ong, Darren Suryawijaya, Bonnici, Rhian, Boniface, Karen, Donato, Celeste M., Mpakiza, Ashley, Meyer, Anell, Bar-Zeev, Naor, Iturriza-Gomara, Miren, Cunliffe, Nigel A., and Danchin, Margaret

Subjects
ROTAVIRUS diseases, ROTAVIRUS vaccines, ENZYME-linked immunosorbent assay, VACCINE effectiveness, ANTIBODY formation
Abstract

High titres of rotavirus-specific maternal antibodies may contribute to lower rotavirus vaccine efficacy in low- and middle-income countries (LMICs). RV3-BB vaccine (G3P[6]) is based on a neonatal rotavirus strain that replicates well in the newborn gut in the presence of breast milk. This study investigated the association between maternal serum antibodies and vaccine response in infants administered the RV3-BB vaccine. Serum was collected antenatally from mothers of 561 infants enrolled in the RV3-BB Phase II study conducted in Blantyre, Malawi, and analysed for rotavirus-specific serum IgA and IgG antibodies using enzyme-linked immunosorbent assay. Infant vaccine take was defined as cumulative IgA seroconversion (≥3 fold increase) and/or stool vaccine shedding. Maternal IgA or IgG antibody titres did not have a negative impact on vaccine-like stool shedding at any timepoint. Maternal IgG (but not IgA) titres were associated with reduced take post dose 1 (p < 0.005) and 3 (p < 0.05) in the neonatal vaccine schedule group but not at study completion (week 18). In LMICs where high maternal antibodies are associated with low rotavirus vaccine efficacy, RV3-BB in a neonatal or infant vaccine schedule has the potential to provide protection against severe rotavirus disease. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Vaccine Take of RV3-BB Rotavirus Vaccine Observed in Indonesian Infants Regardless of HBGA Status.

Author

Donato, Celeste M, Handley, Amanda, Byars, Sean G, Bogdanovic-Sakran, Nada, Lyons, Eleanor A, Watts, Emma, Ong, Darren S, Pavlic, Daniel, Thobari, Jarir At, Satria, Cahya Dewi, Nirwati, Hera, Soenarto, Yati, and Bines, Julie E

Subjects
*ROTAVIRUS vaccines, *IMMUNOGLOBULIN A, *VACCINE effectiveness, *INFANTS, *IMMUNE serums
Abstract

Background Histo-blood group antigen (HBGA) status may affect vaccine efficacy due to rotavirus strains binding to HBGAs in a P genotype–dependent manner. This study aimed to determine if HBGA status affected vaccine take of the G3P[6] neonatal vaccine RV3-BB. Methods DNA was extracted from stool samples collected in a subset (n = 164) of the RV3-BB phase IIb trial in Indonesian infants. FUT2 and FUT3 genes were amplified and sequenced, with any single-nucleotide polymorphisms analyzed to infer Lewis and secretor status. Measures of positive cumulative vaccine take were defined as serum immune response (immunoglobulin A or serum-neutralizing antibody) and/or stool excretion of RV3-BB virus. Participants were stratified by HBGA status and measures of vaccine take. Results In 147 of 164 participants, Lewis and secretor phenotype were determined. Positive vaccine take was recorded for 144 (97.9%) of 147 participants with the combined phenotype determined. Cumulative vaccine take was not significantly associated with secretor status (relative risk, 1.00 [95% CI,.94–1.06]; P =.97) or Lewis phenotype (relative risk, 1.03 [95% CI,.94–1.14]; P =.33), nor was a difference observed when analyzed by each component of vaccine take. Conclusions The RV3-BB vaccine produced positive cumulative vaccine take, irrespective of HBGA status in Indonesian infants. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. “Vaccine take of RV3-BB rotavirus vaccine observed in Indonesian infants regardless of HBGA status”

Author

Donato, Celeste M, primary, Handley, Amanda, additional, Byars, Sean G, additional, Bogdanovic-Sakran, Nada, additional, Lyons, Eleanor A, additional, Watts, Emma, additional, Ong, Darren S, additional, Pavlic, Daniel, additional, Thobari, Jarir At, additional, Satria, Cahya Dewi, additional, Nirwati, Hera, additional, Soenarto, Yati, additional, and Bines, Julie E, additional

Published
2023
Full Text
View/download PDF

6. Wastewater monitoring can anchor global disease surveillance systems

Author

Keshaviah, Aparna, primary, Diamond, Megan B, additional, Wade, Matthew J, additional, Scarpino, Samuel V, additional, Ahmed, Warish, additional, Amman, Fabian, additional, Aruna, Olusola, additional, Badilla-Aguilar, Andrei, additional, Bar-Or, Itay, additional, Bergthaler, Andreas, additional, Bines, Julie E, additional, Bivins, Aaron W, additional, Boehm, Alexandria B, additional, Brault, Jean-Martin, additional, Burnet, Jean-Baptiste, additional, Chapman, Joanne R, additional, Chaudhuri, Angela, additional, de Roda Husman, Ana Maria, additional, Delatolla, Robert, additional, Dennehy, John J, additional, Diamond, Megan Beth, additional, Donato, Celeste, additional, Duizer, Erwin, additional, Egwuenu, Abiodun, additional, Erster, Oran, additional, Fatta-Kassinos, Despo, additional, Gaggero, Aldo, additional, Gilpin, Deirdre F, additional, Gilpin, Brent J, additional, Graber, Tyson E, additional, Green, Christopher A, additional, Handley, Amanda, additional, Hewitt, Joanne, additional, Holm, Rochelle H, additional, Insam, Heribert, additional, Johnson, Marc C, additional, Johnson, Rabia, additional, Jones, Davey L, additional, Julian, Timothy R, additional, Jyothi, Asha, additional, Keshaviah, Aparna, additional, Kohn, Tamar, additional, Kuhn, Katrin G, additional, La Rosa, Giuseppina, additional, Lesenfants, Marie, additional, Manuel, Douglas G, additional, D'Aoust, Patrick M, additional, Markt, Rudolf, additional, McGrath, John W, additional, Medema, Gertjan, additional, Moe, Christine L, additional, Murni, Indah Kartika, additional, Naser, Humood, additional, Naughton, Colleen C, additional, Ogorzaly, Leslie, additional, Oktaria, Vicka, additional, Ort, Christoph, additional, Karaolia, Popi, additional, Patel, Ekta H, additional, Paterson, Steve, additional, Rahman, Mahbubur, additional, Rivera-Navarro, Pablo, additional, Robinson, Alex, additional, Santa-Maria, Monica C, additional, Schmitt, Heike, additional, Smith, Theodore, additional, Stadler, Lauren B, additional, Stassijns, Jorgen, additional, Stenico, Alberta, additional, Street, Renee A, additional, Suffredini, Elisabetta, additional, Susswein, Zachary, additional, Trujillo, Monica, additional, Wolfe, Marlene K, additional, Yakubu, Habib, additional, and Zanoli Sato, Maria Ines, additional

Published
2023
Full Text
View/download PDF

7. Histo-blood group antigen profile of Australian Aboriginal children and seropositivity following oral rotavirus vaccination

Author

Middleton, Bianca F., primary, Danchin, Margie, additional, Cunliffe, Nigel A., additional, Jones, Mark A., additional, Boniface, Karen, additional, Kirkwood, Carl D., additional, Gallagher, Sarah, additional, Kirkham, Lea-Ann, additional, Granland, Caitlyn, additional, McNeal, Monica, additional, Donato, Celeste, additional, Bogdanovic-Sakran, Nada, additional, Handley, Amanda, additional, Bines, Julie E., additional, and Snelling, Thomas L., additional

Published
2023
Full Text
View/download PDF

8. Histo-blood Group Antigen status of Australian Aboriginal children and seropositivity following oral rotavirus vaccination

Author

Middleton, Bianca F., primary, Danchin, Margie, additional, Cunliffe, Nigel A., additional, Jones, Mark A., additional, Boniface, Karen, additional, Kirkwood, Carl D., additional, Gallagher, Sarah, additional, Kirkham, Lea-Ann, additional, Granland, Caitlyn, additional, McNeal, Monica, additional, Donato, Celeste, additional, Bogdanovic-Sakran, Nada, additional, Handley, Amanda, additional, Bines, Julie E., additional, and Snelling, Thomas L., additional

Published
2022
Full Text
View/download PDF

10. The feasibility of SARS-CoV-2 surveillance using wastewater and environmental sampling in Indonesia

Author

Murni, Indah K., primary, Oktaria, Vicka, additional, Handley, Amanda, additional, McCarthy, David T., additional, Donato, Celeste M., additional, Nuryastuti, Titik, additional, Supriyati, Endah, additional, Putri, Dwi Astuti Dharma, additional, Sari, Hendri Marinda, additional, Laksono, Ida Safitri, additional, Thobari, Jarir At, additional, and Bines, Julie E., additional

Published
2022
Full Text
View/download PDF

11. Human Neonatal Rotavirus Vaccine (RV3-BB) to Target Rotavirus from Birth

Author

Bines, Julie E., At Thobari, Jarir, Satria, Cahya Dewi, Handley, Amanda, Watts, Emma, Cowley, Daniel, Nirwati, Hera, Ackland, James, Standish, Jane, Justice, Frances, Byars, Gabrielle, Lee, Katherine J., Barnes, Graeme L., Bachtiar, Novilia S., Icanervilia, Ajeng Viska, Boniface, Karen, Bogdanovic-Sakran, Nada, Pavlic, Daniel, Bishop, Ruth F., Kirkwood, Carl D., Buttery, Jim P., and Soenarto, Yati

Published
2018
Full Text
View/download PDF

13. Neonatal Rotavirus Vaccine (RV3-BB) Immunogenicity and Safety in a Neonatal and Infant Administration Schedule in Malawi:&nbsp;A Randomized, Double-Blind, Four-Arm Parallel Group Dose-Ranging Study

Author

Witte, Desiree, primary, Handley, Amanda, additional, Jere, Khuzwayo C., additional, Bogandovic-Sakran, Nada, additional, Mpakiza, Ashley, additional, Turner, Ann, additional, Pavlic, Daniel, additional, Boniface, Karen, additional, Mandolo, Jonathan, additional, Suryawijaya Ong, Darren, additional, Bonnici, Rhian, additional, Justice, Frances, additional, Bar-Zeev, Naor, additional, Iturriza-Gómara, Miren, additional, Ackland, Jim, additional, Donato, Celeste M., additional, Cowley, Daniel, additional, Barnes, Graeme, additional, Cunliffe, Nigel A., additional, and Bines, Julie E., additional

Published
2021
Full Text
View/download PDF

18. Immunogenicity of four doses of oral poliovirus vaccine when co-administered with the human neonatal rotavirus vaccine (RV3-BB)

Author

Cowley, Daniel, primary, Sari, Rini Mulia, additional, Handley, Amanda, additional, Watts, Emma, additional, Bachtiar, Novilia S., additional, At Thobari, Jarir, additional, Satria, Cahya Dewi, additional, Bogdanovic-Sakran, Nada, additional, Nirwati, Hera, additional, Orsini, Francesca, additional, Lee, Katherine J., additional, Kirkwood, Carl D., additional, Soenarto, Yati, additional, and Bines, Julie E., additional

Published
2019
Full Text
View/download PDF

21. Safety and immunogenicity of RV3-BB human neonatal rotavirus vaccine administered at birth or in infancy: a randomised, double-blind, placebo-controlled trial

Author

Bines, Julie E, primary, Danchin, Margaret, additional, Jackson, Pamela, additional, Handley, Amanda, additional, Watts, Emma, additional, Lee, Katherine J, additional, West, Amanda, additional, Cowley, Daniel, additional, Chen, Mee-Yew, additional, Barnes, Graeme L, additional, Justice, Frances, additional, Buttery, Jim P, additional, Carlin, John B, additional, Bishop, Ruth F, additional, Taylor, Barry, additional, and Kirkwood, Carl D, additional

Published
2015
Full Text
View/download PDF

22. Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours

Author

Kloverpris Henrik, H., Fomsgaard, Anders, Handley, Amanda, Ackland, Jim, Sullivan, Mark, Goulder, Philip, Kloverpris Henrik, H., Fomsgaard, Anders, Handley, Amanda, Ackland, Jim, Sullivan, Mark, and Goulder, Philip

Abstract

Immunotherapies based on reinfusion of autologous cells incubated ex vivo with peptides reconstituted in toxic solvents, such as DMSO, are now performed on a routine basis. However, the toxic effects of the most common solvent used, DMSO, on T cell responses from human PBMCs, have not previously been evaluated in detail. Here, in preparation for a first-in-man human phase I vaccine trial comprising reinfusion of autologous HIV peptide-pulsed PBMCs, human PBMCs from healthy and HIV-infected donors were exposed in vitro to a range of DMSO concentrations, and for a range of time periods. Polychromatic flow cytometry was used to evaluate the influence of DMSO on functional T cell responses. We report that high concentrations of up to 10% of DMSO for 1hour do not affect the cell viability, the magnitude or the functional profile of CD4+ and CD8+ T cell responses, regardless of antigen specificity and HLA class I restriction. In contrast, >2% for >2hours compromises these responses. These data are relevant in the design of immunotherapies based on pulsing a large number of peptides onto antigen presenting cells prior to reinfusion.

Published
2010

23. Non-Immunogenicity of Overlapping Gag Peptides Pulsed on Autologous Cells after Vaccination of HIV Infected Individuals

Author

Kløverpris, Henrik N., primary, Jackson, Akil, additional, Handley, Amanda, additional, Hayes, Peter, additional, Gilmour, Jill, additional, Riddell, Lynn, additional, Chen, Fabian, additional, Atkins, Mark, additional, Boffito, Marta, additional, Walker, Bruce D., additional, Ackland, Jim, additional, Sullivan, Mark, additional, and Goulder, Philip, additional

Published
2013
Full Text
View/download PDF

24. A Randomised, Placebo-Controlled, First-In-Human Study of a Novel Clade C Therapeutic Peptide Vaccine Administered Ex Vivo to Autologous White Blood Cells in HIV Infected Individuals

Author

Jackson, Akil, primary, Kløverpris, Henrik N., additional, Boffito, Marta, additional, Handley, Amanda, additional, Atkins, Mark, additional, Hayes, Peter, additional, Gilmour, Jill, additional, Riddel, Lynn, additional, Chen, Fabian, additional, Bailey-Tippets, Melanie, additional, Walker, Bruce, additional, Ackland, Jim, additional, Sullivan, Mark, additional, and Goulder, Philip, additional

Published
2013
Full Text
View/download PDF

26. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®

Author

von Krempelhuber, Alfred, primary, Vollmar, Jens, additional, Pokorny, Rolf, additional, Rapp, Petra, additional, Wulff, Niels, additional, Petzold, Barbara, additional, Handley, Amanda, additional, Mateo, Lyn, additional, Siersbol, Henriette, additional, Kollaritsch, Herwig, additional, and Chaplin, Paul, additional

Published
2010
Full Text
View/download PDF

27. Control of Viremia and Prevention of AIDS following Immunotherapy of SIV-Infected Macaques with Peptide-Pulsed Blood

Author

De Rose, Robert, primary, Fernandez, Caroline S., additional, Smith, Miranda Z., additional, Batten, C. Jane, additional, Alcântara, Sheilajen, additional, Peut, Vivienne, additional, Rollman, Erik, additional, Loh, Liyen, additional, Mason, Rosemarie D., additional, Wilson, Kim, additional, Law, Matthew G., additional, Handley, Amanda J., additional, and Kent, Stephen J., additional

Published
2008
Full Text
View/download PDF

29. Therapeutic Vaccination of HIV-1-Infected Patients on Haart with a Recombinant HIV-1Nef-Expressing Mva: Safety, Immunogenicity and Influence on Viral Load during Treatment Interruption

Author

Harrer, Ellen, primary, Bäuerle, Michael, additional, Ferstl, Barbara, additional, Chaplin, Paul, additional, Petzold, Barbara, additional, Mateo, Luis, additional, Handley, Amanda, additional, Tzatzaris, Maria, additional, Vollmar, Jens, additional, Bergmann, Silke, additional, Rittmaier, Marion, additional, Eismann, Kathrin, additional, Müller, Sandra, additional, Kalden, Joachim R, additional, Spriewald, Bernd, additional, Willbold, Dieter, additional, and Harrer, Thomas, additional

Published
2005
Full Text
View/download PDF

32. A Randomised, Placebo-Controlled, First-In-Human Study of a Novel Clade C Therapeutic Peptide Vaccine Administered Ex Vivo to Autologous White Blood Cells in HIV Infected Individuals.

Author

Jackson, Akil, Kløverpris, Henrik N., Boffito, Marta, Handley, Amanda, Atkins, Mark, Hayes, Peter, Gilmour, Jill, Riddel, Lynn, Chen, Fabian, Bailey-Tippets, Melanie, Walker, Bruce, Ackland, Jim, Sullivan, Mark, and Goulder, Philip

Subjects
HIV-positive persons, PEPTIDES, LEUCOCYTES, RANDOMIZED controlled trials, T cells, IMMUNOGENETICS, DRUG administration, THERAPEUTICS
Abstract

Background: Preclinical studies of overlapping 15mer peptides, spanning SIV, SHIV or HIV, pulsed on autologous PBMC ex vivo have demonstrated high level, virus-specific T cell responses and viral suppression in non-human primates (NHP). Opal-HIV-Gag(c) consists of 120 synthetic 15mer peptides spanning Clade C, consensus Gag, manufactured to current good manufacturing practice; having been evaluated in a good laboratory practice toxicology study in Macaca mulatta. We evaluated the safety and preliminary immunogenicity of such peptides administered intravenously after short-duration ex vivo incubation, to HIV-positive adults on suppressive antiretroviral therapy. Methods and Findings: A first-in-human, placebo-controlled, double-blind, dose escalation study was conducted. Twenty-three patients with virus suppressed by antiretroviral therapy were enrolled in four groups 12 mg (n = 6), 24 mg (n = 6), 48 mg (n = 2) or matching placebo (n = 8). Treatment was administered intravenously after bedside enrichment of 120 mL whole blood for white cells using a closed system (Sepax S-100 device), with ex vivo peptide admixture (or diluent alone) and 37°C incubation for one hour prior to reinfusion. Patients received 4 administrations at monthly intervals followed by a 12-week observation post-treatment. Opal-HIV-Gag(c) was reasonably tolerated at doses of 12 and 24 mg. There was an increased incidence of temporally associated pyrexia, chills, and transient/self-limiting lymphopenia in Opal-HIV-Gag(c) recipients compared to placebo. The study was terminated early, after two patients were recruited to the 48 mg cohort; a serious adverse event of hypotension, tachycardia secondary to diarrhoea occurred following a single product administration. An infectious cause for the event could not be identified, leaving the possibility of immunologically mediated product reaction. Conclusions: A serious, potentially life-threatening event of hypotension led to early, precautionary termination of the study. In the absence of a clearly defined mechanism or ability to predict such occurrence, further development of Opal-HIV-Gag(c) will not be undertaken in the current form. Registration: ClinicalTrials.gov NCT01123915; EudraCT: 2008-005142-23 [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

33. Therapeutic Vaccination of HIV-1-Infected Patients on Haart with a Recombinant HIV-1 Nef-Expressing Mva: Safety, Immunogenicity and Influence on Viral Load during Treatment Interruption

Author

Harrer, Ellen, Bäuerle, Michael, Ferstl, Barbara, Chaplin, Paul, Petzold, Barbara, Mateo, Luis, Handley, Amanda, Tzatzaris, Maria, Vollmar, Jens, Bergmann, Silke, Rittmaier, Marion, Eismann, Kathrin, Müller, Sandra, Kalden, Joachim R, Spriewald, Bernd, Willbold, Dieter, and Harrer, Thomas

Abstract

The safety and immunogenicity of an HIV-1 nef-expressing modified vaccinia virus Ankara (MVA) was investigated in 14 HIV-1-positive patients (CD4 >400/µl) on highly active antiretroviral therapy (HAART). Patients were vaccinated at weeks 0, 4 and 16, followed by interruption of HAART at week 18. MVA-nefwas well-tolerated except for local reactions, with only mild systemic side effects reported in a few patients. Vaccination with MVA-nefwas associated with recognition of new HIV-1 T-cell epitopes (cytotoxic T-lymphocyte epitopes in 9/14 patients, CD4 epitope/recombinant Nef protein in 2/14) and an increase in CD4+ and CD8+ T cells. All patients had been vaccinated against smallpox and a strong T-cell and antibody response to MVA was induced in all patients. After interruption of HAART, viral load rebounded in all patients, but after a median time of 36 (4–76) weeks in 9/14 patients, viraemia remained below the pre-HAART viral load and CD4 counts stayed above the pre-HAART levels. While six patients have remained off therapy for a median time of 64 (57–76) weeks, HAART was resumed in 8/14 patients after a median treatment interruption time of 15 (4–38) weeks. This study has demonstrated that MVA-nefis safe and immunogenic in HIV-1-infected subjects and has provided encouraging data on the potential of therapeutic vaccinations.

Published
2005
Full Text
View/download PDF

34. Wastewater monitoring can anchor global disease surveillance systems

Author

Keshaviah, Aparna, Diamond, Megan B, Wade, Matthew J, Scarpino, Samuel V, Ahmed, Warish, Amman, Fabian, Aruna, Olusola, Badilla-Aguilar, Andrei, Bar-Or, Itay, Bergthaler, Andreas, Bines, Julie E, Bivins, Aaron W, Boehm, Alexandria B, Brault, Jean-Martin, Burnet, Jean-Baptiste, Chapman, Joanne R, Chaudhuri, Angela, de Roda Husman, Ana Maria, Delatolla, Robert, Dennehy, John J, Diamond, Megan Beth, Donato, Celeste, Duizer, Erwin, Egwuenu, Abiodun, Erster, Oran, Fatta-Kassinos, Despo, Gaggero, Aldo, Gilpin, Deirdre F, Gilpin, Brent J, Graber, Tyson E, Green, Christopher A, Handley, Amanda, Hewitt, Joanne, Holm, Rochelle H, Insam, Heribert, Johnson, Marc C, Johnson, Rabia, Jones, Davey L, Julian, Timothy R, Jyothi, Asha, Kohn, Tamar, Kuhn, Katrin G, La Rosa, Giuseppina, Lesenfants, Marie, Manuel, Douglas G, D'Aoust, Patrick M, Markt, Rudolf, McGrath, John W, Medema, Gertjan, Moe, Christine L, Murni, Indah Kartika, Naser, Humood, Naughton, Colleen C, Ogorzaly, Leslie, Oktaria, Vicka, Ort, Christoph, Karaolia, Popi, Patel, Ekta H, Paterson, Steve, Rahman, Mahbubur, Rivera-Navarro, Pablo, Robinson, Alex, Santa-Maria, Monica C, Schmitt, Heike, Smith, Theodore, Stadler, Lauren B, Stassijns, Jorgen, Stenico, Alberta, Street, Renee A, Suffredini, Elisabetta, Susswein, Zachary, Trujillo, Monica, Wolfe, Marlene K, Yakubu, Habib, and Zanoli Sato, Maria Ines

Abstract

To inform the development of global wastewater monitoring systems, we surveyed programmes in 43 countries. Most programmes monitored predominantly urban populations. In high-income countries (HICs), composite sampling at centralised treatment plants was most common, whereas grab sampling from surface waters, open drains, and pit latrines was more typical in low-income and middle-income countries (LMICs). Almost all programmes analysed samples in-country, with an average processing time of 2·3 days in HICs and 4·5 days in LMICs. Whereas 59% of HICs regularly monitored wastewater for SARS-CoV-2 variants, only 13% of LMICs did so. Most programmes share their wastewater data internally, with partnering organisations, but not publicly. Our findings show the richness of the existing wastewater monitoring ecosystem. With additional leadership, funding, and implementation frameworks, thousands of individual wastewater initiatives can coalesce into an integrated, sustainable network for disease surveillance—one that minimises the risk of overlooking future global health threats.

36. Wastewater-based epidemiology surveillance as an early warning system for SARS-CoV-2 in Indonesia.

Author

Murni IK, Oktaria V, McCarthy DT, Supriyati E, Nuryastuti T, Handley A, Donato CM, Wiratama BS, Dinari R, Laksono IS, Thobari JA, and Bines JE

Subjects
Indonesia epidemiology, Humans, Wastewater-Based Epidemiological Monitoring, COVID-19 epidemiology, COVID-19 diagnosis, COVID-19 virology, SARS-CoV-2 isolation & purification, SARS-CoV-2 genetics, Wastewater virology
Abstract

Background: Wastewater-based epidemiology (WBE) surveillance has been proposed as an early warning system (EWS) for community SARS-CoV-2 transmission. However, there is limited data from low-and middle-income countries (LMICs). This study aimed to assess the ability of WBE surveillance to detect SARS-CoV-2 in formal and informal environments in Indonesia using different methods of sample collection, to compare WBE data with patterns of clinical cases of COVID-19 within the relevant communities, and to assess the WBE potential to be used as an EWS for SARS-CoV-2 outbreaks within a community., Materials and Methods: We conducted WBE surveillance in three districts in Yogyakarta province, Indonesia, over eleven months (27 July 2021 to 7 January 2022 [Delta wave]; 18 January to 3 June 2022 [Omicron wave]). Water samples using grab, and/or passive sampling methods and soil samples were collected either weekly or fortnightly. RNA was extracted from membrane filters from processed water samples and directly from soil. Reverse-transcription quantitative real-time polymerase chain reaction (RT-qPCR) was performed to detect the SARS-CoV-2 N and ORF1ab genes., Results: A total of 1,582 samples were collected. Detection rates of SARS-CoV-2 in wastewater reflected the incidence of community cases, with rates of 85% at the peak to 2% at the end of the Delta wave and from 94% to 11% during the Omicron wave. A 2-week lag time was observed between the detection of SARS-CoV-2 in wastewater and increasing cases in the corresponding community., Conclusion: WBE surveillance for SARS-CoV-2 in Indonesia was effective in monitoring patterns of cases of COVID-19 and served as an early warning system, predicting the increasing incidence of COVID-19 cases in the community., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2024 Murni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results